Pharmaceutical agents that irreversibly block H+-K+ ATPase (the proton pump) in gastric parietal cells, suppressing stomach acid production by 90-95%. PPIs are among the most prescribed medications globally but represent a major cause of acquired hypochlorhydria with cascading consequences for digestion, immune function, and microbiome health.
PPIs (omeprazole, lansoprazole, esomeprazole, pantoprazole) are prodrugs activated in the acidic environment of parietal cell canaliculi, where they form covalent bonds with H+-K+ ATPase, permanently inactivating the enzyme. New proton pumps must be synthesized for acid production to resume (takes 24-72 hours). By raising gastric pH from ~1-2 to 4-6, PPIs create profound downstream effects: (1) Reduced protein digestion (pepsinogen requires acid activation to pepsin), (2) Impaired mineral absorption (iron, calcium, magnesium, B12 require acid), (3) Loss of gastric sterilization barrier (allows bacterial overgrowth and translocation), (4) Altered bile acid metabolism, (5) Compensatory hypergastrinemia (gastrin rises attempting to stimulate acid), (6) Dysbiosis throughout GI tract.
PPIs are massively overprescribed and create the conditions for multiple chronic diseases: SIBO, Clostridium difficile infection, osteoporosis (calcium malabsorption), B12 deficiency, iron-deficiency anemia, increased infection risk, and paradoxically increased reflux upon discontinuation (rebound hyperacidity from hypergastrinemia). In cPNI, identifying PPI use and implementing careful deprescribing protocols (using betaine HCl, digestive enzymes, lifestyle modifications) is essential for restoring gut barrier function.
- Block H+-K+ ATPase irreversibly, requiring new enzyme synthesis
- Suppress acid production by 90-95%
- Raise gastric pH from 1-2 to 4-6
- Among most prescribed medications globally (often inappropriately)
- Two dominant causes of hypochlorhydria: chronic stress and PPIs
- Cause B12 deficiency (requires acid for intrinsic factor release)
- Increase SIBO, C. difficile, pneumonia, bone fracture risk
- Create rebound hyperacidity upon discontinuation
- Require 6-12 week tapering with betaine HCl support for safe discontinuation
- hypochlorhydria — PPIs are dominant acquired cause of low stomach acid
- H+-K+ ATPase — enzyme target irreversibly blocked by PPIs
- gastric acid — secretion suppressed 90-95% by PPIs
- parietal cells — cells in which PPIs block acid-producing proton pumps
- gastrin — compensatory elevation occurs with chronic PPI use
- pepsin — activation from pepsinogen requires acid suppressed by PPIs
- vitamin B12 — absorption impaired by PPI-induced hypochlorhydria
- intrinsic factor — release requires gastric acid suppressed by PPIs
- iron — absorption requires gastric acid; PPI use causes deficiency
- calcium — ionization and absorption impaired by PPIs, increasing fracture risk
- SIBO — risk dramatically increased by loss of gastric acid barrier
- dysbiosis — created throughout GI tract when gastric sterilization is lost
- Clostridium difficile — infection risk increased 2-3x with PPI use
- leaky gut — worsened by PPI-induced dysbiosis and malabsorption
- osteoporosis — risk increased by calcium malabsorption and bone metabolism changes
- betaine HCl — used in cPNI protocols to support deprescribing and restore acid
- chronic stress — other dominant cause of hypochlorhydria (via sympathetic dominance)
- malabsorption — protein, minerals, vitamins all affected by acid suppression
- rebound hyperacidity — occurs upon PPI discontinuation due to hypergastrinemia
- fungal infections — increased risk with loss of gastric acid barrier
- Module 2
- Module 5
- Module 6